Cancer Advisor

Quick Summary: The Patient Blueprint The National Comprehensive Cancer Network (NCCN) provides an authoritative guide to help patients understand pancreatic cancer care . Treatment decisions hinge primarily on resectability —whether the tumor can be cleanly removed by surgery. While surgery offers the best chance for long-term survival, optimal care almost always combines surgery with systemic treatments like chemotherapy and robust supportive care to manage weight loss, digestion, and pain. Receiving a pancreatic cancer diagnosis can feel overwhelming and fast-moving. To help you regain control, the National Comprehensive Cancer Network (NCCN) publishes standard-of-care updates specifically translated for patients and families. The pancreas is a dual-purpose organ: it produces digestive enzymes to break down food and releases hormones like insulin to regulate your blood sugar. When exocrine ...

Quick Summary & Core Update The American Society of Clinical Oncology (ASCO) has released its updated 2026 Living Guideline for Stage IV Non-Small Cell Lung Cancer (NSCLC) Without Driver Alterations . The major takeaway is the addition of retifanlimab-dlwr (an immunotherapy drug sold under the brand name ZYNYZ )  combined with standard chemotherapy as a highly effective first-line treatment option. Clinical trial data shows that adding this drug significantly extends survival and stalls cancer growth compared to chemotherapy alone. When dealing with a diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC) , timing and precision are everything. Because lung cancer research moves incredibly fast, medical organizations utilize what are known as "Living Guidelines" —clinical roadmaps that experts update continuously as soon as groundbreaking clinical trial data breaks. The latest version,...

Abstract Background:  Stage IV pancreatic ductal adenocarcinoma (PDAC) lacking actionable mutations has limited treatment options, with median overall survival (mOS) of 9–11 months using standard chemotherapy. Repurposed drugs (ivermectin, mebendazole) and hyperthermia show preclinical promise. This in silico randomized controlled trial (RCT) evaluates an integrative protocol combining ivermectin, mebendazole, hyperthermia, supplements, and lifestyle interventions versus standard-of-care (SOC) NALIRIFOX chemotherapy in non-BRCA-mutated stage IV PDAC. Methods:  A simulated two-arm RCT enrolled 200 patients with non-BRCA-mutated stage IV PDAC, randomized 1:1 to an experimental arm (ivermectin 1 mg/kg/day 3 days/week, mebendazole 500 mg twice daily, localized hyperthermia 42–43°C 3 sessions/week, supplements [vitamin C, vitamin D, curcumin, berberine], ketogenic diet, intermittent fasting, pancreatic enzymes) or control arm (NALIRIFOX). Primary endpoint was 12-month overall surv...

Abstract Background: Stage 4 prostate cancer has a 5-year survival rate of 37% with standard of care (SOC, e.g., androgen deprivation therapy [ADT], chemotherapy, Lu-177-PSMA-617). An optimized intervention combining repurposed drugs, supplements, diet/lifestyle, hyperthermia, and SOC components may improve outcomes. Methods : We simulated a double-blind RCT with 1,000 patients (500 per arm) with non-BRCA-mutated stage 4 prostate cancer (70% mHSPC, 30% mCRPC), comparing an integrative multimodal intervention arm (ivermectin 1.0–1.5 mg/kg/day (cycled 3 weeks on/1 off), mebendazole 500–1,500 mg/day (titrated), metformin 1,700 mg/day, vitamin C 1 g/kg IV 3 times/week, vitamin D 5,000 IU/day, curcumin 1,000 mg/day, low-glycemic Mediterranean diet, exercise, MBSR, hyperthermia [modulated electro-hyperthermia at 42°C for 60 minutes, 2–3 times weekly], plus ADT/Lu-177-PSMA-617) to a placebo arm with SOC. Primary endpoint was overall survival (OS); secondary endpoints included progression-fre...

Optimized for Medical Professionals and Patient Advocates | Last Updated: June 2026 Looking for the latest prostate cancer screening guidelines? This comprehensive guide merges and updates the latest protocols from the National Comprehensive Cancer Network (NCCN) and the European Association of Urology (EAU). Discover risk-stratified PSA test age milestones, the revolutionary "MRI-first" diagnostic pathway, and modern clinical consensus to maximize early detection while minimizing over-treatment. Table of Contents 1. The Shift in Prostate Cancer Screening Paradigms 2. NCCN vs. EAU Risk-Stratified Screening Matrix 3. The Modern 3-Step Diagnostic Pathway (MRI-First) 4. Post-Biopsy Risk Classification & Active Surveillance 5. Shared Decision-Making (SDM) Checklist for Patients 6. Frequently Asked Questions (FAQ) ...